Botensilimab
- Generic Name
- Botensilimab
- Drug Type
- Biotech
- CAS Number
- 2408310-37-0
- Unique Ingredient Identifier
- 1Z5YC3ME5N
- Background
Botensilimab is under investigation in clinical trial NCT03860272 (Fc-engineered Anti-ctla-4 Monoclonal Antibody in Advanced Cancer).
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations
- Conditions
- Resectable MMR-deficient Solid TumorsResectable MMR-proficient Solid Tumors
- Interventions
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 92
- Registration Number
- NCT06279130
- Locations
- 🇳🇱
The Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands
Botensilimab and Balstilimab Optimization in Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Nicholas DeVito, MD
- Target Recruit Count
- 15
- Registration Number
- NCT06268015
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
- Conditions
- Unresectable Esophageal AdenocarcinomaUnresectable Gastric CarcinomaUnresectable Gastric AdenocarcinomaUnresectable Gastroesophageal Junction AdenocarcinomaMetastatic Esophageal CancerMetastatic Gastric CarcinomaMetastatic Esophageal CarcinomaAdvanced Unresectable Gastric AdenocarcinomaMetastatic Esophageal AdenocarcinomaMetastatic Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT06251973
- Locations
- 🇺🇸
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
The Seven Trial: Exploiting the Unfolded Protein Response
- Conditions
- Pancreatic Cancer MetastaticPancreatic Adenocarcinoma Metastatic
- Interventions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- HonorHealth Research Institute
- Target Recruit Count
- 18
- Registration Number
- NCT06076837
- Locations
- 🇺🇸
Clinical Trials Nurse Navigator, Scottsdale, Arizona, United States
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
- Conditions
- Advanced Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Michael B. Atkins, MD
- Target Recruit Count
- 120
- Registration Number
- NCT05928806
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Georgetown University, Washington, District of Columbia, United States
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
- Conditions
- Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeNewly Diagnosed GlioblastomaGliosarcomaGlioblastoma Multiforme
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 25
- Registration Number
- NCT05864534
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
- Conditions
- Colorectal CancerResectable Colorectal Carcinoma
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 112
- Registration Number
- NCT05845450
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Lombardia/MI, Italy
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
- Conditions
- Advanced Colorectal AdenocarcinomaAdvanced Microsatellite Stable Colorectal CarcinomaMetastatic Colorectal AdenocarcinomaMetastatic Microsatellite Stable Colorectal CarcinomaStage III Colorectal Cancer AJCC V8Stage IV Colorectal Cancer AJCC V8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed Tomography
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 63
- Registration Number
- NCT05672316
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
- Conditions
- Pancreatic CancerAdvanced Pancreatic Ductal AdenocarcinomaPancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Bruno Bockorny
- Target Recruit Count
- 24
- Registration Number
- NCT05632328
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT05630183
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸USC Norris Oncology, Newport Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.